22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:40 , Jul 7, 2017 |  BioCentury  |  Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
00:45 , Jun 24, 2017 |  BioCentury  |  Strategy

Takeda’s modality operandi

Takeda Pharmaceutical Co. Ltd. is moving beyond its traditional small molecule approach into new modalities with the goal of delivering therapeutics that provide a step change for patients. To get there, Takeda is using a...
21:58 , May 26, 2017 |  BC Extra  |  Company News

FDA expands Zykadia's label to first-line NSCLC

FDA granted regular approval to Zykadia ceritinib from Novartis AG (NYSE:NVS; SIX:NOVN) for the first-line treatment of metastatic non-small cell lung cancer in anaplastic lymphoma kinase (ALK)-positive patients. The small molecule ALK inhibitor had accelerated...
16:06 , May 4, 2017 |  BC Week In Review  |  Clinical News

FDA approves Takeda's Alunbrig

FDA granted accelerated approval to Alunbrig brigatinib (AP26113) from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in patients who have progressed on, or are intolerant...
22:26 , Apr 28, 2017 |  BC Extra  |  Company News

FDA approves Takeda's Alunbrig

FDA granted accelerated approval to Alunbrig brigatinib from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to...
22:45 , Apr 7, 2017 |  BioCentury  |  Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
22:47 , Feb 8, 2017 |  BC Week In Review  |  Clinical News

Brigatinib regulatory update

Ariad submitted an MAA to EMA for brigatinib to treat metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in adults who have been previously treated with Xalkori crizotinib. The MAA is based on...
02:02 , Jan 14, 2017 |  BioCentury  |  Strategy

Solidifying Takeda’s position

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Ariad Pharmaceuticals Inc. should be the boost the pharma needs to hit $10 billion in cancer sales by 2025, as the biotech’s brigatinib is expected to lead Takeda’s...